CALGB 9710 Protokolü
İndüksiyon Tedavisi
All trans retinoic acid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
Daunorubicin 50 mg/m2/d iv d3-6
Konsolidasyon Tedavisi
Arsenic Trioxide (As2O3) 0.15 mg/kg/d x 5d/week for 5 wks x 2 Kürs (Kür 2 starts after 2 wks rest)
followed by
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-7 x 2 Kürs
Daunorubicin 50 mg/m2/d iv d1-3 x 2 Kür
İdame Tedavisi
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-7 qow x 1 year
6-Mercaptopurine (6-MP) 60 mg/m2 po qd x 1 year
Methotrexate (MTX) 20 mg/m2 po qw x 1 year.
EAPLG Protokolü
Yaş < 60 and WBC < 10,000/uL
İndüksiyon Tedavisi
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
Daunorubicin 60 mg/m2/d iv d3-5
Konsolidasyon Tedavisi
Kür 1
Cytarabine (Ara-C) 200 mg/m2/d civi d1-7
Daunorubicin 60 mg/m2/d iv d1-3
Kür 2
Cytarabine (Ara-C) 1000 mg/m2 iv q12h x 8 doses
Daunorubicin 45 mg/m2/d iv d1-3
İdame Tedavisi
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
Methotrexate (MTX) 15 mg/m2 po qw x 2 year
Yaş < 60 and WBC > 10,000/uL
İndüksiyon Tedavisi
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
Daunorubicin 60 mg/m2/d iv d3-5
Konsolidasyon Tedavisi
Kür 1
Cytarabine (Ara-C) 200 mg/m2/d civi d1-7
Daunorubicin 60 mg/m2/d iv d1-3
Intrathecal Cytarabine (Ara-C) 50 mg and Methotrexate (MTX) 15 mg x 3
Kür 2
Cytarabine (Ara-C) 2000 mg/m2 iv q12h x 10 doses
Daunorubicin 45 mg/m2/d iv d1-3
Intrathecal Cytarabine (Ara-C) 50 mg and Methotrexate (MTX) 15 mg x 2
İdame Tedavisi
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
Methotrexate (MTX) 15 mg/m2 po qw x 2 year
Yaş > 60 and WBC < 10,000/uL
İndüksiyon Tedavisi
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
Daunorubicin 60 mg/m2/d iv d3-5
Konsolidasyon Tedavisi
Kür 1
Daunorubicin 60 mg/m2/d iv d1-3
Kür 2
Daunorubicin 45 mg/m2/d iv d1-3
İdame Tedavisi
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
Methotrexate (MTX) 15 mg/m2 po qw x 2 year
Yaş > 60 and WBC > 10,000/uL
İndüksiyon Tedavisi
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
Daunorubicin 60 mg/m2/d iv d3-5
Konsolidasyon Tedavisi
Kür 1
Cytarabine (Ara-C) 200 mg/m2/d civi d1-7
Daunorubicin 60 mg/m2/d iv d1-3
Intrathecal Cytarabine (Ara-C) 50 mg and Methotrexate (MTX) 15 mg x 3
Kür 2
Cytarabine (Ara-C) 1000 mg/m2 iv q12h x 8 doses
Daunorubicin 45 mg/m2/d iv d1-3
Intrathecal Cytarabine (Ara-C) 50 mg and Methotrexate (MTX) 15 mg x2
İdame Tedavisi
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
Methotrexate (MTX) 15 mg/m2 po qw x 2 year
ATRA + Arsenic Trioxide
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till CR
Arsenic Trioxide (As2O3) 0.15 mg/kg/d iv over 1 h d10 till CR
If WBC > 10 x 109/L, add
Gemtuzumab 9 mg/m2 iv d1 and/or
Idarubicin 12 mg/m2/d iv d1-4
Once CR obtained, change to
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses 2 wks on and 2 wks off x 28 wks
Arsenic Trioxide (As2O3) 0.15 mg/kg/d iv d1-5 qw 4 wks on and 4 wks off x 28 wks